Exploring the role of the MAX gene in small cell lung cancer and other neuroendocrine tumors
Investigating Max as a tumor suppressor gene in small cell lung cancer and other neuroendocrine tumors
This study is looking at how a gene called MAX helps prevent small cell lung cancer and other similar tumors from growing, and it hopes to find new ways to treat these cancers by understanding what happens when this gene is missing.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10811720 on NIH RePORTER |
What this research studies
This research investigates how the MAX gene functions as a tumor suppressor in small cell lung cancer (SCLC) and other neuroendocrine tumors. By using advanced techniques like CRISPR to manipulate gene expression, the study aims to understand the biological effects of MAX deletion on tumor growth and stability. Patients may benefit from insights gained about the mechanisms of their cancer, potentially leading to new therapeutic strategies. The research will also analyze gene interactions and expressions to provide a comprehensive view of tumor behavior.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with small cell lung cancer or other neuroendocrine tumors.
Not a fit: Patients with non-neuroendocrine tumors or those without a diagnosis of small cell lung cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with small cell lung cancer and other neuroendocrine tumors.
How similar studies have performed: Previous research has shown promising results in understanding the role of tumor suppressor genes in cancer, suggesting that this approach could yield valuable insights.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Eisenman, Robert Neil — Fred Hutchinson Cancer Center
- Study coordinator: Eisenman, Robert Neil
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.